Neurotech USA Inc is a private clinical stage biotech company based in Cumberland, RI, specializing in the development of transformative therapies for chronic eye diseases. Their core platform technology, Encapsulated Cell Therapy (ECT), enables continuous production of therapeutic proteins to the eye, with a particular focus on improving the quality of life for individuals with chronic retinal diseases.
One of the therapeutic areas of focus for Neurotech is Macular Telangiectasia (MacTel), a bilateral retinal disease that gradually leads to the loss of central vision. Through their ECT platform, Neurotech releases Ciliary Neurotrophic Factor (CNTF), a protein that has shown promise in protecting against the progressive loss of photoreceptors. With no known pharmacological treatment options available for MacTel, Neurotech's innovative approach offers hope for patients experiencing blurring, distorted vision, trouble reading, and central vision loss.
Generated from the website